Commentary: Biosimilars are coming, and patients could benefit

03/6/2009 | Genetic Engineering & Biotechnology News

Regulating the development of follow-on biologics as recommended in President Barack Obama's first budget could benefit patients if the law "appropriately balances the need for competition with the need to protect innovation," writes James Bianco, CEO and director of Cell Therapeutics. The law should help bring follow-on biologics to the market quickly but only after their safety and efficacy have been tested in clinical trials, Bianco writes.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA